Orion Portfolio Solutions LLC Has $3.16 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Orion Portfolio Solutions LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 16,103 shares of the medical research company’s stock after selling 216 shares during the period. Orion Portfolio Solutions LLC’s holdings in IQVIA were worth $3,164,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Pictet Asset Management Holding SA increased its position in IQVIA by 12.7% in the 4th quarter. Pictet Asset Management Holding SA now owns 105,227 shares of the medical research company’s stock valued at $20,678,000 after acquiring an additional 11,839 shares in the last quarter. Broadway Wealth Solutions Inc. bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $274,000. New Age Alpha Advisors LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $4,565,000. Providence Capital Advisors LLC lifted its holdings in IQVIA by 0.8% during the 4th quarter. Providence Capital Advisors LLC now owns 22,264 shares of the medical research company’s stock worth $4,375,000 after buying an additional 173 shares in the last quarter. Finally, Norges Bank bought a new position in IQVIA in the 4th quarter valued at $336,041,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of NYSE IQV opened at $176.28 on Tuesday. The company has a fifty day moving average price of $192.73 and a 200 day moving average price of $205.61. The firm has a market cap of $31.08 billion, a PE ratio of 23.50, a PEG ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1-year low of $169.37 and a 1-year high of $253.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Morgan Stanley upped their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Robert W. Baird reduced their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Truist Financial reissued a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Barclays cut their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.